about
Consumer/patient encounters with prescription drug monitoring programs: evidence from a Medicaid populationKentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drugSmoking characteristics among lesbian, gay, and bisexual adultsMenthol cigarette smoking among lesbian, gay, bisexual, and transgender adults.Prescription drug monitoring program utilization in Kentucky community pharmacies.Smoking Cessation Awareness and Utilization Among Lesbian, Gay, Bisexual, and Transgender Adults: An Analysis of the 2009-2010 National Adult Tobacco Survey.Online medical care: the current state of "eVisits" in acute primary care delivery.Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment.Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents.The Power and Pitfalls of Big Data Research in Obstetrics and Gynecology: A Consumer's Guide.Pharmacists' role in harm reduction: a survey assessment of Kentucky community pharmacists' willingness to participate in syringe/needle exchange.Smoke-free policy implementation: theoretical and practical considerations.Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment.Patient and hospital characteristics predictive of inferior vena cava filter usage in venous thromboembolism patients: A study from the 2013 to 2014 Nationwide Readmissions Database.Hospitalization metrics associated with hospital-level variation in inferior vena cava filter utilization for patients with venous thromboembolism in the United States: Implications for quality of careA Review of Interventions to Increase Vena Cava Filter Retrieval RatesPrevalence of substance use disorder and psychiatric comorbidity burden among pregnant women with opioid use disorder in a large administrative database, 2009-2014Development and Validation of an Administrative Claims-based Measure for All-cause 30-day Risk-standardized Readmissions After Discharge From Inpatient Psychiatric FacilitiesChanges in Opioid Use After Florida's Restriction Law for Acute Pain PrescriptionsSubstance Use and School Characteristics in Lesbian, Gay, Bisexual, and Heterosexual High School StudentsMass Casualty Shooting Venues, Types of Firearms, and Age of Perpetrators in the United States, 1982-2018The prevalence of drivers under the influence of medical cannabis must be considered within proper contextPerinatal Navigator Approach to Smoking Cessation for Women With Prevalent Opioid DependenceHealthcare Utilization and Physical Functioning in Older Adults in the United StatesWe Cannot Treat the DeadRapid Expansion of the Opioid Ecosystem: National Implications for Prescriber-Pharmacist CommunicationThe American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: commentMental health disparities and high-risk alcohol use among non-heterosexual high school studentsAssessing the utility of the Healthy Start Screen to predict an elevated Edinburgh Postnatal Depression Scale scorePrevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015Perception of prescription drug monitoring programs as a prevention tool in primary medical careAppalachian disparities in tobacco cessation treatment utilization in MedicaidCharacteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry
P50
Q27003444-1EEAC18A-5418-4044-8ED9-93C5B7614744Q35136698-76352A17-BB41-4563-AD27-2260BB872A11Q35329650-F0F0CB4A-7AAA-406B-81BA-9523FAE0A464Q35680042-6D8BE7E7-9750-4D9B-BF7F-327917517711Q35788530-023E708C-69CC-49C4-83F0-02F87BA711FFQ36862507-6B630A99-A6A5-46E3-BD51-D3DCF20CF6D2Q38282985-EDB9E6F2-6C3B-440F-9BAD-2DA0B2CD802CQ38689763-80E95C84-8E12-4985-97A3-B70672BF5CE3Q44343000-F69BA539-09A9-416E-85D8-FADEAB15EE0FQ47143545-0A3AECB6-9FE6-4368-AB42-056CBE8BEF43Q47164500-8F7A7EFA-B71A-4B9E-99F0-CCCF81AC2BD1Q48164359-434F7A4C-F6CD-4DFF-BB54-1B2242476E3DQ51668304-2E18B609-0B4F-4A8E-904C-4D3BCED44441Q55004302-C34FC0A0-B889-426C-84D2-3DFCCAB0C4B6Q55303987-4D310256-CF7D-4B83-90C5-35E3C75497A4Q57173798-A3223677-10CA-474A-8FC8-FFA2DCB6CAC5Q88360619-DD05528B-C0CA-4154-BDBF-5E678AAAF4F7Q89751080-18EB61C6-8DE7-4E87-A4A7-B158E456738CQ89918785-C7780F22-48F2-4ADB-B766-65ADA7FD33E9Q89934229-5CB8C50B-37AD-47E0-B20C-1D6D623298AFQ91022668-3C711162-C5BB-42D2-B8F3-B4FCECFDF46CQ91104279-86BC1F83-8D1F-4FF8-AE6A-CDA53A554C19Q91311323-02D72707-ADDC-4F41-8C65-508381DA2299Q91367808-550C763C-11AB-49A1-8E90-AFDEEE234C4FQ91392819-919F0084-F9FC-4FB5-B4BF-5099F7C731F6Q91401830-277F3EA3-1023-4F7A-BD93-F868862B1AB8Q91464545-13C837B3-DE24-43E6-8146-424A3590EB25Q91625471-EE5CFFCB-D832-4E1A-98BC-F9AE186817DAQ91841934-D2278D1B-5A39-420B-96FC-CD94214A2AC0Q91891283-4EA975CB-7A2C-43F1-88CA-68C12B3DDF06Q92287365-695B8941-F285-4537-A39F-5D28CD41DF0AQ92762841-FCBADD35-CD3E-4598-A971-F8F2655AFDDAQ92778387-23BFF85E-0DD6-41F2-BB61-D6B71B801009Q93184673-D4C50ED5-DDDD-4E5E-9CA9-CF4FC9CC9C0A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amie J Goodin
@ast
Amie J Goodin
@en
Amie J Goodin
@es
Amie J Goodin
@fr
Amie J Goodin
@nl
Amie J Goodin
@sl
type
label
Amie J Goodin
@ast
Amie J Goodin
@en
Amie J Goodin
@es
Amie J Goodin
@fr
Amie J Goodin
@nl
Amie J Goodin
@sl
altLabel
A Goodin
@en
AJ Goodin
@en
Amie Goodin
@en
Amie J Goodin
@en
prefLabel
Amie J Goodin
@ast
Amie J Goodin
@en
Amie J Goodin
@es
Amie J Goodin
@fr
Amie J Goodin
@nl
Amie J Goodin
@sl
P106
P21
P31
P496
0000-0002-0020-8720